Established by Integra Holdings in 2017. Nectin therapeutics' antibodies are based on the discoveries and inventions made by Prof. Ofer Mandelboim from the Immunology & Cancer Research Center at the Hebrew University and Prof. Stipan Jonjic from the Department of Histology and Embryology/Center for Proteomics, Faculty of Medicine, University of Rijeka. Integra Holdings & Yissum are the
The first generation of antibodies that block immune
checkpoint-targets was recently introduced to clinical usage.
It revolutionized the field of cancer therapy and offered new hope for patients. Yet,
many patients do not benefit from these drugs, such that additional antibodies to block other immune checkpoint molecules are much needed.
Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies.
Prof. Jonjic is a principal investigator and a Professor at the Faculty of Medicine at the University of Rijeka in Croatia where he also serves as the chairman of the Department for Histology and Embryology and the Chair of the Center for Proteomics. Prof. Jonjic is a world leader in the field of viral immunology. Over the years he was awarded with many grants and prizes for his achievements and held many executive positions within the University of Rijeka and in national Croatian societies. He is also a member of the German National Academy of Science - LEOPOLDINA, and a board member of several leading scientific journals. In 2006 Prof. Jonjic established the Center for Proteomics which specializes in the generation of monoclonal antibodies in a high-throughput manner. Later, he has established a modern animal facility to further support the development of biomedical science. Prof. Jonjic’s group has more than dozen active collaborations with various research institutions in Europe, US and Canada. Nectin’s pipeline is the outcome of his collaboration with Prof. Mandelboim.
Prof. Mandelboim is a principal investigator and a Professor at the Hebrew University of Jerusalem, Israel, where he leads a research laboratory and serves as the head of the Lautenberg Center for General and Tumor Immunology, and the head of the Department of Immunology and Cancer Research. Prof. Mandelboim received his Ph.D. in Immunology from the Weizmann Institute of Science followed by a post-doctorate fellowship at the Harvard Medical School. He then joined the Department of Immunology and Cancer Research at the Faculty of Medicine at the Hebrew University, to establish a laboratory of NK cell biology. To this date, Prof. Mandelboim published more than 180 scientific papers, participated in 3 EU consortium grants, in two Marie Curie student network grants, and won an ERC advanced grant. He obtained grants in a total sum of more than 15,000,000 Euro, received more than 20 awards, and supervised more than 50 Ph.D. students.
Dr. Cinamon has a vast experience in leading early stage drug development. After a post-doctorate fellowship at the University of California, San Francisco, Dr. Cinamon joined Teva Pharmaceutical Industries where he was a Director and held a Project Champion position. In this role he led many early stage projects of both auto-immune and cancer related indications, overseeing all aspects of drug development. He next moved to Quiet Therapeutics, where he held a position of VP Pre-Clinical Development & GM, leading the development of a targeted drug against cancer, based on nanoparticles. Dr. Cinamon received his Ph.D. in Immunology from the Weizmann Institute of Science.
Dr. Tsukerman received his Ph.D. from the Hebrew University at the lab of Prof. Mandelboim. During his Ph.D., Dr. Tsukerman authored over 20 publications and numerous patents. Dr. Tsukerman is an expert in the field of cellular and molecular immunology with vast experience in generation of novel therapeutic agents, such as monoclonal antibodies and fusion proteins for treatment of cancer. Dr. Tsukerman is the recipient of numerous excellence awards including Bester award for cancer research and Kaye innovation award.
Mail: firstname.lastname@example.org | Tel: +972-(0)54-424-7524
Address: Nectin Therapeutics Ltd., Hi-Tech Campus Givat Ram, Jerusalem, Israel POB 39135 Zip 91390